Role of palliative SBRT in barcelona clinic liver cancer-stageC hepatocellular carcinoma patients.

Abstract

To evaluate the role of palliative stereotactic body radiation therapy (SBRT) in Barcelona Clinic Liver Cancer stage‑C (BCLC-C) hepatocellular carcinoma (HCC) patients who are not suitable for other loco-regional therapies. It is an observational retrospective study done between May 2020 and September 2021. The data were collected from 35patients of advanced HCC who underwent SBRT. Patients of Child Pugh status (CPs) A5-B7 and with aliver reserve of ≥ 700cc were included. Local control (LC), overall survival (OS) and adverse events including decompensation were carefully recorded. In the cohort, Portal vein and IVC tumor thrombosis were present in 33(94.3%) and 8(22.85%) patients, respectively. Lung and nodal metastasis were found in 11(31.4%) and 21(60%) of patients, respectively. The median gross tumor volume (GTV) was 563cc (range 80-1925cc). The median SBRT dose prescription was 35 Gy (range 25-40 Gy) in 5-10 fractions. Post radiation therapy, there was improvement in pain and discomfort in24 out of29 (82.75%) and18 out of23 (78%) patients respectively. Also bone metastasis related pain was improved in all3 (100%) patients. One year LC, and OS were 80% and 30% respectively. On multivariate analysis, the GTV volume > 750cc and PIVKA-II > 8000 mAU/ml remained the predictor factor for poor OS. Post SBRT, change in child-pugh score by 1point was observed in 7patients (20%) which was managed conservatively. SBRT is asafe and feasible option for BCLC‑C HCC. It not only improves the quality of life by symptom control but also results in good LC and OS with acceptable toxicity. SBRT should be considered in amultidisciplinary fashion for patients presenting with advanced HCCs.